Fast Approval Of Pandemic Flu Vaccines With Adjuvants Could Face Regulatory Barrier
This article was originally published in The Pink Sheet Daily
Current FDA regulations may pose a barrier to fast approval of pandemic influenza vaccines that include an adjuvant for novel strains, HHS' National Vaccine Program Office says.
You may also be interested in...
Each company will manufacture 8,000 doses of the avian strain under contracts with the National Institutes of Health. Aventis will perform stability testing to see if its vaccine is suitable for stockpiling.
CBER Office of Vaccine Research & Review Acting Director William Egan says that naive adults are similar to children when it comes to vaccine dosing. NIH is conducting studies on strains to which the population is naive.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.